現代藥理研究指出肉蓯蓉粗萃取物有抗發炎的作用 74 與加強學習記 憶的功效75，而肉蓯蓉與成骨細胞的研究並不多且不明確，因此我們 選定肉蓯蓉粗萃取物來做進一步的探討。
如何促進成骨細胞來增強造骨作用，主要透過增加成骨細胞的數 目，或者是增強成骨細胞功能來達到造骨的目的。前者可以透過MTT assay 來測量細胞 proliferation 的速度，而後者可以透過礦化作用來觀 察。根據本實驗發現，在老鼠成骨細胞株中，肉蓯蓉粗萃取物對於成 骨細胞的proliferation 與 migration 皆無明顯的影響。而在礦化方面，
依本篇的實驗結果可知，肉蓯蓉粗萃取物對於促進礦化的形成的確是
第六章 結論
綜合以上本篇所完成的實驗可知，在老鼠成骨細胞中給予肉蓯蓉 粗萃取物，可以藉由活化 ERK、JNK、p38、Akt 等蛋白，促使轉錄 因子p65 作用，使得 BMP-2、ALP 與 OPN 的表現量增加。此外能促 進成骨細胞礦化程度之提升，但是對於細胞的移行和增生能力並無明 顯效果。
參考文獻
1. Yang NP, Jen I, Chuang SY, Chen SH, Chou P. Screening for low bone mass with quantitative ultrasonography in a community without dual-energy X-ray absorptiometry: population-based survey. BMC Musculoskelet Disord. 2006;7:24.
2. Jilka RL. Biology of the basic multicellular unit and the pathophysiology of osteoporosis. Med Pediatr Oncol.
2003;41(3):182-185.
3. 孟景春，周仲瑛：中醫學概論，知音出版社，1994。
4. Chapurlat RD, Delmas PD. Bone microdamage: a clinical perspective. Osteoporos Int. 2009;20(8):1299-1308.
5. Hadjidakis DJ, Androulakis, II. Bone remodeling. Ann N Y Acad Sci. 2006;1092:385-396.
6. Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem. 1994;55(3):273-286.
7. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21(2):115-137.
8. Raisz LG. Physiology and pathophysiology of bone remodeling.
Clin Chem. 1999;45(8 Pt 2):1353-1358.
9. Khosla S. Minireview: the OPG/RANKL/RANK system.
Endocrinology. 2001;142(12):5050-5055.
10. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H. Severe osteoporosis in mice lacking osteoclastogenesis
inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun.
1998;247(3):610-615.
11. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical
need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res. 2005;20(2):177-184.
12. Coetzee M, Kruger MC. Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment? South Med J. 2004;97(5):506-511.
13. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA.
Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet.1999;353(9156):878-882.
14. Adachi JD, Papaioannou A. Corticosteroid-Induced osteoporosis:
detection and management. Drug Saf. 2001;24(8):607-624.
15. 洪瑞國：老年人發生第二次對側髖骨骨折之保護及危險因子之 分析及探討Assessment of Protective and Risk Factors of the
Second Contralateral Hip Fracture in the Elderly。醫務管理研究所，
國立陽明大學，2010。
16. 李瑋君，韓岳津，吳英黛，曹昭懿：骨質疏鬆相關骨折住院病 患之健保申報分析。臺灣醫學. 2007;11 卷(1 期):頁 22-28。
17. Dannemann C, Gratz KW, Riener MO, Zwahlen RA. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone. 2007;40(4):828-834.
18. Barrier A, Lescaille G, Rigolet A, Descroix V, Goudot P, Ruhin B.
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. Rev Stomatol Chir Maxillofac. 2010;111(4):196-202.
19. Zografos GN, Georgiadou D, Thomas D, Kaltsas G, Digalakis M.
Drug-induced esophagitis. Dis Esophagus. 2009;22(8):633-637.
20. Goltzman D. Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov. 2002;1(10):784-796.
21. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results
From the Women's Health Initiative randomized controlled trial.
JAMA. 2002;288(3):321-333.
22. Chesnut CH, 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C,
Peacock M, Richardson P, Watts N, Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med.
2000;109(4):267-276.
23. Urist MR. Bone: formation by autoinduction.
Science.1965;150(698):893-899.
24. Reddi AH. Marshall R. Urist: a renaissance scientist and orthopaedic surgeon. J Bone Joint Surg Am. 2003;85-A Suppl 3:3-7.
25. Xiao YT, Xiang LX, Shao JZ. Bone morphogenetic protein.
Biochem Biophys Res Commun. 2007;362(3):550-553.
26. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA. Novel regulators of bone formation:
molecular clones and activities. Science.
1988;242(4885):1528-1534.
27. Zhao M, Harris SE, Horn D, Geng Z, Nishimura R, Mundy GR, Chen D. Bone morphogenetic protein receptor signaling is
necessary for normal murine postnatal bone formation. J Cell Biol.
2002;157(6):1049-1060.
28. Matsumoto A, Yamaji K, Kawanami M, Kato H. Effect of aging on bone formation induced by recombinant human bone
morphogenetic protein-2 combined with fibrous collagen membranes at subperiosteal sites. J Periodontal Res.
2001;36(3):175-182.
29. Fleet JC, Cashman K, Cox K, Rosen V. The effects of aging on the
bone inductive activity of recombinant human bone morphogenetic protein-2. Endocrinology. 1996;137(11):4605-4610.
30. Zmuda JM, Sheu YT, Moffett SP. The search for human osteoporosis genes. J Musculoskelet Neuronal Interact.
2006;6(1):3-15.
31. Styrkarsdottir U, Cazier JB, Kong A, Rolfsson O, Larsen H, Bjarnadottir E, Johannsdottir VD, Sigurdardottir MS, Bagger Y, Christiansen C, Reynisdottir I, Grant SF, Jonasson K, Frigge ML, Gulcher JR, Sigurdsson G, Stefansson K. Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biol.
2003;1(3):E69.
32. Balcerzak M, Hamade E, Zhang L, Pikula S, Azzar G, Radisson J, Bandorowicz-Pikula J, Buchet R. The roles of annexins and
alkaline phosphatase in mineralization process. Acta Biochim Pol.
2003;50(4):1019-1038.
33. Seibel MJ. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol. 2005;2(10):504-517; quiz 501 p following 533.
34. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell.
1979;16(4):885-893.
35. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med. 2000;11(3):279-303.
36. Klein-Nulend J, Roelofsen J, Semeins CM, Bronckers AL, Burger EH. Mechanical stimulation of osteopontin mRNA expression and synthesis in bone cell cultures. J Cell Physiol.
1997;170(2):174-181.
37. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS.
Osteopontin as a means to cope with environmental insults:
regulation of inflammation, tissue remodeling, and cell survival. J
Clin Invest. 2001;107(9):1055-1061.
38. Raouf A, Seth A. Discovery of osteoblast-associated genes using cDNA microarrays. Bone. 2002;30(3):463-471.
39. Ishijima M, Tsuji K, Rittling SR, Yamashita T, Kurosawa H, Denhardt DT, Nifuji A, Ezura Y, Noda M. Osteopontin is required for mechanical stress-dependent signals to bone marrow cells. J Endocrinol. 2007;193(2):235-243.
40. 李雪靖，郭鴻：原發性骨質疏松癥中醫藥治療概況。河北醫藥 研究Association of Kidney Vacuity, Bone Mineral Density and Tooth Mobility in Postmenopausal Women。中國醫學研究所，中 國醫藥學院1997。
48. 陳雅吟：停經後婦女骨質疏鬆症與中醫腎虛證相關性之研究 The association between postmenopausal osteoporosis and Kidney- vacuity syndrome in Chinese Medicine。中國醫學研究所，中國 醫藥學院1997。
49. Xu H, Lawson D, Kras A, Ryan D. The use of preventive strategies for bone loss. Am J Chin Med. 2005;33(2):299-306.
50. 顏正華：中藥學，知音出版社，1991。
51. 王輝武：中醫百家藥論薈萃，重慶出版社，1997。
52. 凌一揆：中藥學，知音出版社，2004。
53. 徐雅慧，羅吉方，張憲昌，林哲輝：市售肉蓯蓉藥材之鑑別。
藥物食品檢驗局調查研究年報2007(25 號):110-118。
54. Johnson GL, Lapadat R. Mitogen-activated protein kinase
pathways mediated by ERK, JNK, and p38 protein kinases. Science.
2002;298(5600):1911-1912.
55. Xiao G, Jiang D, Thomas P, Benson MD, Guan K, Karsenty G, Franceschi RT. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem.
2000;275(6):4453-4459.
56. Hu Y, Chan E, Wang SX, Li B. Activation of p38 mitogen-activated protein kinase is required for osteoblast differentiation.
Endocrinology. 2003;144(5):2068-2074.
57. Ge C, Xiao G, Jiang D, Franceschi RT. Critical role of the
extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J Cell Biol.
2007;176(5):709-718.
58. Matsuguchi T, Chiba N, Bandow K, Kakimoto K, Masuda A, Ohnishi T. JNK activity is essential for Atf4 expression and late-stage osteoblast differentiation. J Bone Miner Res.
2009;24(3):398-410.
59. Mukherjee A, Rotwein P. Akt promotes BMP2-mediated osteoblast differentiation and bone development. J Cell Sci. 2009;122(Pt 5):716-726.
60. Vallabhapurapu S, Karin M. Regulation and function of
NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693-733.
61. Boyce BF, Yao Z, Xing L. Functions of nuclear factor kappaB in bone. Ann N Y Acad Sci. 2010;1192:367-375.
62. 關儉，唐潔鳳，郭榮林：六味地黃丸對絕經后骨質疏松患者骨
密度的干預研究。海南醫學2009(05):79-80。 礎醫學雜志2006(12):918-920。
65. Hung TY, Chen TL, Liao MH, Ho WP, Liu DZ, Chuang WC, Chen RM. Drynaria fortunei J. Sm. promotes osteoblast maturation by inducing differentiation-related gene expression and protecting against oxidative stress-induced apoptotic insults. J
Ethnopharmacol. 2010;131(1):70-77.
66. Sun JS, Dong GC, Lin CY, Sheu SY, Lin FH, Chen LT, Chang WH, Wang YJ. The effect of Gu-Sui-Bu (Drynaria fortunei J. Sm)
immobilized modified calcium hydrogenphosphate on bone cell activities. Biomaterials. 2003;24(5):873-882.
67. Sun JS, Theriault BL, Anderson GI. The effect of Gu-Sui-Bu (Drynaria fortunei) on bone cell activity. Am J Chin Med.
2004;32(5):737-753.
68. Wang XL, Wang NL, Zhang Y, Gao H, Pang WY, Wong MS, Zhang G, Qin L, Yao XS. Effects of eleven flavonoids from the osteoprotective fraction of Drynaria fortunei (KUNZE) J. SM. on osteoblastic proliferation using an osteoblast-like cell line. Chem Pharm Bull (Tokyo). 2008;56(1):46-51.
69. Jeong JC, Kang SK, Youn CH, Jeong CW, Kim HM, Lee YC, Chang YC, Kim CH. Inhibition of Drynariae Rhizoma extracts on bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts. Int Immunopharmacol. 2003;3(12):1685-1697.
70. Jeong JC, Lee JW, Yoon CH, Lee YC, Chung KH, Kim MG, Kim CH. Stimulative effects of Drynariae Rhizoma extracts on the
proliferation and differentiation of osteoblastic MC3T3-E1 cells. J Ethnopharmacol. 2005;96(3):489-495.
71. Wong RW, Rabie AB. Systemic effect of crude extract from
rhizome of Drynaria fortunei on bone formation in mice. Phytother Res. 2006;20(4):313-315.
72. Li G, Zhang XA, Zhang JF, Chan CY, Yew DT, He ML, Lin MC, Leung PC, Kung HF. Ethanol extract of Fructus Ligustri Lucidi promotes osteogenesis of mesenchymal stem cells. Phytother Res.
2010;24(4):571-576.
73. Yen ML, Su JL, Chien CL, Tseng KW, Yang CY, Chen WF, Chang CC, Kuo ML. Diosgenin induces hypoxia-inducible factor-1
activation and angiogenesis through estrogen receptor-related phosphatidylinositol 3-kinase/Akt and p38 mitogen-activated protein kinase pathways in osteoblasts. Mol Pharmacol.
2005;68(4):1061-1073.
74. Lin LW, Hsieh MT, Tsai FH, Wang WH, Wu CR. Anti-nociceptive and anti-inflammatory activity caused by Cistanche deserticola in rodents. J Ethnopharmacol. 2002;83(3):177-182.
75. Choi JG, Moon M, Jeong HU, Kim MC, Kim SY, Oh MS.
Cistanches Herba enhances learning and memory by inducing nerve growth factor. Behav Brain Res. 2011;216(2):652-658.
附錄
中藥 乾重(mg/ml)
山藥 31
巴戟天 32
肉蓯蓉 13
淫羊藿 21
杜仲 7
續斷 16
骨碎補 17
補骨脂 15
菟絲子 24
熟地黃 14
女貞子 34
山茱萸 37
感謝由侯庭鏞教授所提供之十二種中藥粗萃取物乾重資料
Effects of Cistanche deserticola crude extract on the activity of osteoblast Name: Hsin-Chih Huang
Major Professor's Name: Wen-Chi Chen Graduate Institute of Chinese Medicine
Osteoporosis frequently occurs in women after menopause, often caused fracture of vertebral body, hip and wrist. About ten percent of human bone role in the effect of bone remodeling includes both bone formation and dissolution. Osteoporosis took place by the unbalance of these two effects. Osteoblasts make bone formation and in this study we explore Chinese herbal medicine for the activity of osteoblast.
Our study used twelve selected common Bushen chinese herbal medicine crude extracts and MC3T3-E1 osteoblast cell line. Our research divided into two parts. The first part was to evaluate the effect of the twelve Bushen chinese herbal medicine crude extracts on MC3T3-E1 osteoblast cell line. Then we selected one of the effective drugs C.
deserticola to make more advanced study. Our results revealed C.
deserticola promote cell activity and mineralization in MC3T3-E1 osteoblast cell line. According to the results of this study, C. deserticola extracts provide a new direction for the treatment of osteoporosis.
Key words: Chinese herbal medicine, Cistanche deserticola, osteoblast, osteoporosis
謝詞
本論文特別感謝中國醫藥大學中西醫結合研究所所長陳汶吉教 授，中國醫藥大學中醫學系學士班中醫基礎學科主任李德茂副教授，
中國醫藥大學中醫學系學士班中醫外傷學科暨中國附醫骨科部馮逸 卿副教授，中國醫藥大學醫學院醫學系學士班藥理學科湯智昕副教授，
在這兩年的時間中予以耐心指導。
此外還要感謝中國醫藥大學中醫學系侯庭鏞教授提供的中藥粗 萃取物，使得實驗得以順利完成。感謝中山醫學大學醫學研究所楊順 發副教授在口試時予以指導，使得論文內容更臻完備。
最後感謝在這兩年裡對我鼓勵與支持的家人和同伴，感謝你們。